NEWTON, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. ( ALNA), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today announced that company management will present at the Stifel 2021 Virtual Healthcare Conference being held November 15th-17th 2021.
Please see the details for the presentation below:
| Stifel 2021 Virtual Healthcare Conference | |
| Date: | 8:40 a.m. ET |
| Time: | Wednesday, November 17th, 2021 |
| Webcast: | https://wsw.com/webcast/stifel58/alna/2067120 |
Management will also be available for 1x1 meetings. If you would like to request a meeting, please email [email protected].
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program recently initiated.
Investor Contact
Ashley Robinson
LifeSci Advisors, LLC
617-430-7577
[email protected]
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]
